Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Three-Period, Six-Sequence Crossover Study in Healthy Volunteers to Compare the Relative Bioavailability of Itraconazole Tablet (T26) and Itraconazole Capsule (Sporanox®) Under Fed Conditions and to Assess the Food Effect on T26

16 de noviembre de 2026 actualizado por: Triastek, lnc.

This is a phase 1, randomized, open-label, single-center, single-dose, three-period, six-sequence crossover study in healthy adult volunteers. The study is designed to compare the relative bioavailability of itraconazole tablet (T26, Test) with itraconazole capsule (Sporanox®, Reference) under fed conditions; and to assess the food effect from a high-fat meal on T26.

Three treatments, as described below, are planned:

Test Product (Tfed): T26, 130 mg (two 65 mg tablets), administered under fed conditions Reference Product (R): Sporanox®, 200 mg (two 100 mg capsules), administered under fed conditions Test Product (Tfasted): T26, 130 mg (two 65 mg tablets), administered under fasted conditions A total of 18 participants will be randomized 1:1:1:1:1:1 into six different treatment sequences (TfastTfedR, TfastRTfed, TfedTfastR, TfedRTfast, RTfastTfed, RTfedTfast). The dosing between two consecutive treatment periods will be separated by a minimum 14-day washout interval.

This study consists of three periods: a screening period (Day -7~Day -2), a cross-over treatment period, and a safety follow-up visit (Day 36 ~Day 43). During each treatment period, eligible participants will be admitted to the clinical research unit (CRU) one day prior to dosing and will receive a single oral dose of the assigned study treatment on Day 1 according to the randomized sequence. On Day 1 of each treatment period, T26 or Sporanox® will be administered with 240 mL of water at approximately 8:00 a.m. (±1 hour) under fasted or fed condition. Detailed dietary requirements and dosing procedures. Participants will discharge from the CRU on the fifth day of each treatment period after completion of the scheduled safety assessments and collection of the last PK blood sample (up to 96 hours post-dose).

Descripción general del estudio

Estado

Aún no reclutando

Tipo de estudio

Intervencionista

Inscripción (Estimado)

18

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • NA, Municipality
      • Chongqing, NA, Municipality, Porcelana, 400020
        • No. 1, Jialing Yicun, Liangjiang New Area, Chongqing
        • Contacto:
          • Liangying Liu
          • Número de teléfono: +86-13436012840
          • Correo electrónico: 37145266@qq.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Healthy male and female participants aged 18 years and above (including 18 years).

  2. Male participants with body weight ≥50.0 kg and female participants with body weight ≥45.0 kg. Body Mass Index (BMI) = weight (kg) / height² (m²), within the range of 18.5-30.0 kg/m² (inclusive).

  3. Participants with no history of chronic or serious diseases of the cardiovascular, digestive, urinary, respiratory, hematologic/lymphatic, endocrine, immune, psychiatric, or nervous systems, and in good general health.

  4. Participants must be willing to use effective contraception from screening until 2 months after the last dose of the final treatment cycle.

    a) Female participants must: i. Be of non-child-bearing potential i.e. surgically sterilized or postmenopausal, or ii. If of child-bearing potential, must have a negative pregnancy test at Screening and within 24 hours prior to treatment Day 1. They must agree not to attempt to become pregnant, must not donate ova, and must agree to use two forms of highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug, OR use 1 form of highly effective contraceptive method, plus an additional barrier method of contraception between signing consent, during the study, and at least 2 months after the last dose of study drug.

    iii. Women of childbearing potential (WCBP) with same sex partners who abstain from penile- vaginal intercourse are eligible if such is their preferred and usual lifestyle.

    c) Male participants must: i. Be willing not to donate sperm until at least 2 months after the last dose of study drug and.

    ii. If engaging in sexual intercourse with a female partner who could become pregnant, be willing to use a condom in addition to having the female partner use a highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug.

  5. Voluntarily sign an informed consent form prior to the trial, with full understanding of the trial content, procedures, and potential adverse reactions, and be able to communicate effectively with investigators.

  6. Capable of completing the study in accordance with the trial protocol requirements.

Exclusion Criteria:

  1. Vital signs, physical examination, hearing assessment, laboratory tests (hematology, urinalysis, blood chemistry, coagulation panel), infectious disease panel, 12-lead ECG, etc., showing clinically significant abnormalities;
  2. (Inquiry) Smoking 5 or more cigarettes per day on average within 3 months prior to screening, or unable to refrain from using any tobacco product within 48 h prior to administration and during hospitalization;
  3. (Inquiry) History of acute infectious disease with significant antibiotic use within 3 months before screening, or mild infectious disease within 7 days before first dose;
  4. (Inquiry) History of allergy to itraconazole, other azoles, or any excipients of the investigational product, or allergy to two or more substances;
  5. (Inquiry) Alcohol consumption >14 units per week within 3 months before screening (1 unit = 17.7 mL ethanol, equivalent to ~354 mL of 5% beer, ~44 mL of 40% spirits, or ~147 mL of 12% wine), or unable to abstain from alcohol-containing products during the study, or positive alcohol breath test;
  6. (Inquiry) Received blood transfusion, donated blood, or experienced major blood loss (≥400 mL) within 3 months before first dose;
  7. (Inquiry) Vaccinated within 14 days before first dose, or planning vaccination during the study period;
  8. (Inquiry) Taken any prescription medication, over-the-counter medication, vitamin products, or herbal supplements within 2 weeks before first dose;
  9. (Inquiry) Participants who, within 72 hours prior to the first dose, have consumed special diet (including dragon fruit, mango, grapefruit, etc.), or consumed foods or beverages containing caffeine or rich in xanthine (such as chocolate, strong tea, coffee, cola, animal offal), engaged in vigorous exercise, or have other factors affecting drug absorption, distribution, metabolism, or excretion;
  10. (Inquiry + System Search) Used other investigational products or participated in clinical drug trials within 3 months before first dose;
  11. Experienced acute illness or required concomitant medication from screening until first dose;
  12. Female participants who are breastfeeding or have a positive pregnancy test results at screening or during the study period;
  13. History of drug abuse within the past year, or illicit drug use within 3 months before screening, or positive drug abuse screening test;
  14. (Inquiry) Dysphagia, lactose intolerance (e.g., history of diarrhea after milk consumption), or inability to comply with standardized diet;
  15. (Inquiry) History of diseases that may affect safety or pharmacokinetics of the investigational product, such as gastric spasms, gastroesophageal reflux disease, Crohn's disease, chronic atrophic gastritis, Sjögren's syndrome, pernicious anemia, etc., or currently having any of these conditions;
  16. (Inquiry) Post-partial gastrectomy, or major surgery within 6 months before screening, or planning surgery during the study, or history of surgery affecting drug absorption, distribution, metabolism, or excretion (except appendectomy);
  17. (Inquiry + System Search) History of serious conditions judged by the investigator as clinically significant in the cardiovascular system (including congestive heart failure, coronary atherosclerotic heart disease, valvular heart disease, arrhythmia, torsades de pointes), hepatic system (active liver disease), urinary system, digestive system, respiratory system (including chronic obstructive pulmonary disease, cystic fibrosis), hematologic/lymphatic system (e.g., neutropenia), nervous system, psychiatric system, visual disorders/abnormalities, auditory disorders (including tinnitus and sudden deafness), malignant tumors, or currently having any of these conditions;
  18. (Inquiry) Use of any drugs known to interact with itraconazole within 4 weeks before screening [including methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (e.g., dihydroergotamine, ergometrine, ergotamine, methylergometrine), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, levacetylmethadol (levomethadyl), halofantrine, astemizole, mizolastine, terfenadine, sertindole, bepridil, lercanidipine, ivabradine, domperidone, colchicine, fesoterodine, telithromycin, solifenacin, erythromycin, clarithromycin, etc.];
  19. (Inquiry) Female participants who have used long-acting estrogen or progestogen injections or implants within 6 months before the study, or short-acting contraceptives within 30 days before the study;
  20. (Inquiry) History of vasovagal syncope from blood or needles, or unable to tolerate venipuncture;
  21. Participants unable to complete the study due to other reasons;
  22. Participants judged by the investigator to have other factors unsuitable for participation in this study;
  23. Participants with creatinine clearance <80 mL/min (calculated using Cockcroft-Gault formula: CrCl = [(140 - age) × weight (kg)] / [0.818 × serum creatinine (μmol/L)]; for females, multiply result by 0.85);
  24. (Inquiry) Participants with decreased gastric acidity, such as participants taking gastric acid secretion suppressors (e.g., H₂-receptor antagonists, proton pump inhibitors) or participants with achlorhydria caused by certain diseases.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tfasted-Tfed-R group

Test Product

Reference Product

Experimental: Tfasted-R-Tfed group

Test Product

Reference Product

Experimental: Tfed-Tfasted-R group

Test Product

Reference Product

Experimental: Tfed-R-Tfasted group

Test Product

Reference Product

Experimental: R-Tfasted-Tfed group

Test Product

Reference Product

Experimental: R-Tfed-Tfasted group

Test Product

Reference Product

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cmax
Periodo de tiempo: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose
AUC0-tlast
Periodo de tiempo: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose
AUC0-inf
Periodo de tiempo: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Tmax
Periodo de tiempo: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
t₁/₂
Periodo de tiempo: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
Kel
Periodo de tiempo: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
F
Periodo de tiempo: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
CL/F
Periodo de tiempo: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
Vz/F
Periodo de tiempo: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
AUC_%Extrap
Periodo de tiempo: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

16 de noviembre de 2026

Finalización primaria (Estimado)

19 de diciembre de 2026

Finalización del estudio (Estimado)

1 de febrero de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • T26-101

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir